Cardiovascular Systems Stock
Your prediction
Pros and Cons of Cardiovascular Systems in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cardiovascular Systems vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Cardiovascular Systems | - | - | - | - | - | - | - |
Orasure Tech | 3.660% | 4.508% | -7.273% | -17.742% | -31.544% | -33.351% | -40.725% |
scPharmaceuticals | 6.760% | 8.867% | -3.493% | -56.667% | -23.130% | -10.526% | - |
SI-BONE Inc | 1.500% | 3.053% | -3.571% | -37.500% | -28.947% | -51.087% | - |
News
Novo Nordisk Arms Wegovy to Be a Triple Threat
Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S (NYSE: NVO). Originally purposed for Type 2 diabetes, the skyrocketing off-label